Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2011

01.11.2011 | Original Article

The Role of Preoperative [18F]Fluorodeoxyglucose Positron Emission Tomography in Predicting Early Recurrence After Curative Resection of Hepatocellular Carcinomas

verfasst von: Sung Gwe Ahn, Sung Hoon Kim, Tae Joo Jeon, Ho Jin Cho, Sae Byeol Choi, Mi Jin Yun, Jong Doo Lee, Kyung Sik Kim

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scan reflects tumor differentiation and predicts clinical outcome in patients with hepatocellular carcinoma (HCC). We investigated the correlation of PET scans with tumor differentiation and early tumor recurrence (time-to-recurrence <1 year).

Methods

We reviewed the medical records of 93 patients with HCC who underwent curative resection at our hospital from August 2004 through December 2008. PET scans were performed preoperatively, and the maximum standardized uptake value of the tumor (SUVtumor) and the tumor-to-non-tumor SUV ratio (TNR) were calculated from FDG uptake.

Results

Twenty-six (27.9%) had recurrences and 12 of them (46.2%) had early recurrences. SUVtumor and TNR correlated strongly with tumor differentiation (p < 0.001). Early recurrence-free and the overall survival rates in the low TNR group (TNR <2.0) were higher than in the high TNR group (TNR ≥2.0) (p = 0.015, p = 0.013). According to univariate analysis, predictors of early tumor recurrence were large tumor size (≥5 cm), high TNR (≥2), high SUVtumor (≥4), and high Edmoson–Steiner grade. However, on multivariate analysis, none of the examined factors were statistically significant independent predictor.

Conclusion

PET scans reflect tumor differentiation in HCCs. Because high TNR (TNR ≥2) and SUVtumor (SUV ≥4) were these cutoff point significant predictors in univariate analysis, future studies with more statistical power are needed to assess the significance.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr;55(2):74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr;55(2):74–108.PubMedCrossRef
2.
Zurück zum Zitat Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004 Apr;130(4):187–96.PubMedCrossRef Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004 Apr;130(4):187–96.PubMedCrossRef
3.
Zurück zum Zitat Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009 Dec;15 Suppl 6:S50-9PubMedCrossRef Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009 Dec;15 Suppl 6:S50-9PubMedCrossRef
4.
Zurück zum Zitat Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 2006 Feb;202(2):275–83.PubMedCrossRef Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 2006 Feb;202(2):275–83.PubMedCrossRef
5.
Zurück zum Zitat Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991 Aug;214(2):114–7.PubMedCrossRef Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991 Aug;214(2):114–7.PubMedCrossRef
6.
Zurück zum Zitat Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg 1990 Jan;211(1):28–33.PubMedCrossRef Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg 1990 Jan;211(1):28–33.PubMedCrossRef
7.
Zurück zum Zitat Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991 Nov;14(5):802–5.PubMedCrossRef Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991 Nov;14(5):802–5.PubMedCrossRef
8.
Zurück zum Zitat Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000 Aug 1;89(3):500–7.PubMedCrossRef Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000 Aug 1;89(3):500–7.PubMedCrossRef
9.
Zurück zum Zitat Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007 Mar;141(3):330–9.PubMedCrossRef Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007 Mar;141(3):330–9.PubMedCrossRef
10.
Zurück zum Zitat Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007 Nov;47(5):584–90.CrossRef Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007 Nov;47(5):584–90.CrossRef
11.
Zurück zum Zitat Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996 Sep;111(3):720–6.PubMedCrossRef Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996 Sep;111(3):720–6.PubMedCrossRef
12.
Zurück zum Zitat Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 1989 Mar;9(3):457–60.PubMedCrossRef Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 1989 Mar;9(3):457–60.PubMedCrossRef
13.
Zurück zum Zitat Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC. Overexpression of KIAA010 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2007 Sep;15(18 Pt 1):5368–76.CrossRef Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC. Overexpression of KIAA010 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2007 Sep;15(18 Pt 1):5368–76.CrossRef
14.
Zurück zum Zitat Regimebeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma:results of a multicenter study. J Surg Oncol 2004 Jan;85(1):36–41.CrossRef Regimebeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma:results of a multicenter study. J Surg Oncol 2004 Jan;85(1):36–41.CrossRef
15.
Zurück zum Zitat Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999 Oct;17(10):3201–6. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999 Oct;17(10):3201–6.
16.
Zurück zum Zitat Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002 Feb 12;86(4):512–6. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002 Feb 12;86(4):512–6.
17.
Zurück zum Zitat Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003 Jul 1;102(1):53–9.PubMedCrossRef Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003 Jul 1;102(1):53–9.PubMedCrossRef
18.
Zurück zum Zitat Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, et al. 18 F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997 Feb 15;79(4):695–9.PubMedCrossRef Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, et al. 18 F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997 Feb 15;79(4):695–9.PubMedCrossRef
19.
Zurück zum Zitat Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004 Dec;31(12):1621–30.PubMedCrossRef Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004 Dec;31(12):1621–30.PubMedCrossRef
20.
Zurück zum Zitat Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007 Jan 15;13(2 Pt 1):427–33.PubMedCrossRef Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007 Jan 15;13(2 Pt 1):427–33.PubMedCrossRef
21.
Zurück zum Zitat Okabe H, Satoh S, Furukawa Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003 Jun; 63(12):3043–8.PubMed Okabe H, Satoh S, Furukawa Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003 Jun; 63(12):3043–8.PubMed
22.
Zurück zum Zitat Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996 Dec;23(12):1641–74.PubMedCrossRef Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996 Dec;23(12):1641–74.PubMedCrossRef
23.
Zurück zum Zitat Schroder O,Trojan J, Zeuzem S, Baum RP. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37(8):279–85.PubMed Schroder O,Trojan J, Zeuzem S, Baum RP. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37(8):279–85.PubMed
24.
Zurück zum Zitat Eary JF, Conrad EU. Positron EmissionTomography in Grading SoftTissue Sarcomas. SeminMusculoskelet Radiol 1999;3(2):135–8.CrossRef Eary JF, Conrad EU. Positron EmissionTomography in Grading SoftTissue Sarcomas. SeminMusculoskelet Radiol 1999;3(2):135–8.CrossRef
25.
Zurück zum Zitat Stokkel MP, ten Broek FW, van Rijk PP. The role of FDGPET in the clinicalmanagement of head and neck cancer. Oral Oncol Nov 1998 Nov;34(6):466–71.CrossRef Stokkel MP, ten Broek FW, van Rijk PP. The role of FDGPET in the clinicalmanagement of head and neck cancer. Oral Oncol Nov 1998 Nov;34(6):466–71.CrossRef
26.
Zurück zum Zitat Okazumi S, Isono K, Enomoto K, et al. Evaluationof liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. JNuclMed 1992 Mar;33(3):333–9. Okazumi S, Isono K, Enomoto K, et al. Evaluationof liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. JNuclMed 1992 Mar;33(3):333–9.
27.
Zurück zum Zitat Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992 Sep-Oct;16(5):684–9.PubMedCrossRef Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992 Sep-Oct;16(5):684–9.PubMedCrossRef
28.
Zurück zum Zitat Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001 Jun;96(6):1877–80.PubMedCrossRef Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001 Jun;96(6):1877–80.PubMedCrossRef
29.
Zurück zum Zitat Delbeke D, MartinWH, Sandler MP, ChapmanWC, Wright JK, Pinson CW. Evaluation of benign vs malignant hepaticle sions with positron emission tomography. Arch Surg 1998 May;133(5):510–5; discussion 515–6.PubMedCrossRef Delbeke D, MartinWH, Sandler MP, ChapmanWC, Wright JK, Pinson CW. Evaluation of benign vs malignant hepaticle sions with positron emission tomography. Arch Surg 1998 May;133(5):510–5; discussion 515–6.PubMedCrossRef
30.
Zurück zum Zitat Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999 Nov;94(11):3314–9.PubMedCrossRef Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999 Nov;94(11):3314–9.PubMedCrossRef
31.
Zurück zum Zitat Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995 Oct;36(10):1811–7.PubMed Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995 Oct;36(10):1811–7.PubMed
32.
Zurück zum Zitat Court WS, Order SE, Siegel JA, et al. Remission and survival following monthly intra-arterial cisplatinum in nonresectable hepatoma. Cancer Invest. 2002;20(5–6):613–25.PubMedCrossRef Court WS, Order SE, Siegel JA, et al. Remission and survival following monthly intra-arterial cisplatinum in nonresectable hepatoma. Cancer Invest. 2002;20(5–6):613–25.PubMedCrossRef
33.
Zurück zum Zitat Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008 May;38(5):474–483.PubMedCrossRef Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008 May;38(5):474–483.PubMedCrossRef
34.
Zurück zum Zitat Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009 May;50(5):682–7.PubMedCrossRef Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009 May;50(5):682–7.PubMedCrossRef
35.
Zurück zum Zitat Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001 Feb;28(2):117–122PubMedCrossRef Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001 Feb;28(2):117–122PubMedCrossRef
36.
Zurück zum Zitat Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003 Feb;44(2):213–21.PubMed Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003 Feb;44(2):213–21.PubMed
37.
Zurück zum Zitat Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for dectection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008 Dec;49(12):1912–21.PubMedCrossRef Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for dectection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008 Dec;49(12):1912–21.PubMedCrossRef
Metadaten
Titel
The Role of Preoperative [18F]Fluorodeoxyglucose Positron Emission Tomography in Predicting Early Recurrence After Curative Resection of Hepatocellular Carcinomas
verfasst von
Sung Gwe Ahn
Sung Hoon Kim
Tae Joo Jeon
Ho Jin Cho
Sae Byeol Choi
Mi Jin Yun
Jong Doo Lee
Kyung Sik Kim
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1660-1

Weitere Artikel der Ausgabe 11/2011

Journal of Gastrointestinal Surgery 11/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.